These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10083368)

  • 1. Mechanisms underlying the development of T-cell tolerance following interruption of signalling at the CD28/B7 and CD40/gp39 interface.
    Rastellini C; Salam A; Kuddus R; Aitouche A; Braun M; Leach R; Peach R; Fung JJ; Starzl TE; Rao AS
    Transplant Proc; 1999; 31(1-2):845. PubMed ID: 10083368
    [No Abstract]   [Full Text] [Related]  

  • 2. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of immunological tolerance to islet allografts.
    Rossini AA; Parker DC; Phillips NE; Durie FH; Noelle RJ; Mordes JP; Greiner DL
    Cell Transplant; 1996; 5(1):49-52. PubMed ID: 8665076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the CD28/B7 and CD40/CD40L costimulatory pathways does not ameliorate chronic rejection in a mouse aortic allograft model of direct antigen presentation.
    Tang JL; Woodward JE; Subbotin V; Logar AJ; Sun H; Valdivia LA; Schaefer AT; Zottola LB; Peach R; Fung JJ; Rao AS
    Transplant Proc; 2001; 33(1-2):382. PubMed ID: 11266872
    [No Abstract]   [Full Text] [Related]  

  • 6. Blockade of costimulation prevents infection-induced immunopathology in interleukin-10-deficient mice.
    Villegas EN; Wille U; Craig L; Linsley PS; Rennick DM; Peach R; Hunter CA
    Infect Immun; 2000 May; 68(5):2837-44. PubMed ID: 10768980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells.
    Eck SC; Turka LA
    Cancer Immunol Immunother; 1999 Sep; 48(6):336-41. PubMed ID: 10473809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous blockade of B7-CD28 and CD40-CD40L costimulation eliminates the direct xenorestricted human anti-porcine T-cell response.
    Popma SH; Krasinskas AM; Kreisel D; Szeto W; McLean AD; Moore JS; Rosengard BR
    Transplant Proc; 2001; 33(1-2):767-9. PubMed ID: 11267061
    [No Abstract]   [Full Text] [Related]  

  • 9. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
    Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
    J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymic medullary epithelium and thymocyte self-tolerance require cooperation between CD28-CD80/86 and CD40-CD40L costimulatory pathways.
    Williams JA; Zhang J; Jeon H; Nitta T; Ohigashi I; Klug D; Kruhlak MJ; Choudhury B; Sharrow SO; Granger L; Adams A; Eckhaus MA; Jenkinson SR; Richie ER; Gress RE; Takahama Y; Hodes RJ
    J Immunol; 2014 Jan; 192(2):630-40. PubMed ID: 24337745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance.
    Phillips NE; Markees TG; Mordes JP; Greiner DL; Rossini AA
    J Immunol; 2003 Mar; 170(6):3015-23. PubMed ID: 12626555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.
    Rastellini C; Salam A; Kuddus R; Aitouche A; Subbotin V; Braun M; Leach R; Peach R; Fung JJ; Starzl TE; Rao AS
    Transplant Proc; 1999; 31(1-2):1242-3. PubMed ID: 10083554
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.
    Williams MA; Trambley J; Ha J; Adams AB; Durham MM; Rees P; Cowan SR; Pearson TC; Larsen CP
    J Immunol; 2000 Dec; 165(12):6849-57. PubMed ID: 11120808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor.
    Kalinichenko TV; Mokyr MB
    Cancer Immunol Immunother; 1998 Aug; 46(6):293-303. PubMed ID: 9756413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to islet xenografts induced by dual manipulation of antigen presentation and co-stimulation.
    Markees TG; Appel MC; Noelle RJ; Mordes JP; Greiner DL; Rossini AA
    Transplant Proc; 1996 Apr; 28(2):814-5. PubMed ID: 8623413
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
    Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
    Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing.
    Zhan Y; Brady JL; Sutherland RM; Lew AM
    J Immunol; 2001 Dec; 167(11):6279-85. PubMed ID: 11714791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of costimulation to enhance tumor immunity.
    Vesosky B; Hurwitz AA
    Cancer Immunol Immunother; 2003 Nov; 52(11):663-9. PubMed ID: 12920481
    [No Abstract]   [Full Text] [Related]  

  • 19. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells.
    Pericle F; Epling-Burnette PK; Podack ER; Wei S; Djeu JY
    J Leukoc Biol; 1997 Feb; 61(2):201-8. PubMed ID: 9021926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking T-cell costimulation to prevent transplant rejection.
    Zheng XG; Turka LA
    Transplant Proc; 1998 Aug; 30(5):2146-9. PubMed ID: 9723421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.